Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Monte Rosa Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Monte Rosa Therapeutics, Inc.’s stock price such as:

• Monte Rosa Therapeutics, Inc.’s current stock price and volume
• Why Monte Rosa Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for GLUE from analysts
• GLUE’s stock price momentum as measured by its relative strength

About Monte Rosa Therapeutics, Inc. (GLUE)

Before we jump into Monte Rosa Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Want to learn more about Monte Rosa Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Monte Rosa Therapeutics, Inc..

Monte Rosa Therapeutics, Inc.’s Stock Price as of Market Close

As of June 11, 2025, 12:59 PM, CST, Monte Rosa Therapeutics, Inc.’s stock price was $5.180.

Monte Rosa Therapeutics, Inc. is up 1.97% from its previous closing price of $5.080.

During the last market session, Monte Rosa Therapeutics, Inc.’s stock traded between $5.070 and $5.260. Currently, there are approximately 82.15 million shares outstanding for Monte Rosa Therapeutics, Inc..

Monte Rosa Therapeutics, Inc.’s price-earnings (P/E) ratio is currently at 66.0, which is high compared to the Biotechnology industry median of 21.2. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Monte Rosa Therapeutics, Inc. Stock Price History

Monte Rosa Therapeutics, Inc.’s (GLUE) price is currently up 23.93% so far this month.

During the month of June, Monte Rosa Therapeutics, Inc.’s stock price has reached a high of $5.260 and a low of $4.088.

Over the last year, Monte Rosa Therapeutics, Inc. has hit prices as high as $12.400 and as low as $3.210. Year to date, Monte Rosa Therapeutics, Inc.’s stock is down 25.36%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Monte Rosa Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there were 3 analysts who downgraded Monte Rosa Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Monte Rosa Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Monte Rosa Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Monte Rosa Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Monte Rosa Therapeutics, Inc. (GLUE) by visiting AAII Stock Evaluator.

Relative Price Strength of Monte Rosa Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, Monte Rosa Therapeutics, Inc. has a weighted four-quarter relative price strength of 1.36%, which translates to a Momentum Score of 63 and is considered to be Strong.

Want to learn more about how Monte Rosa Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Monte Rosa Therapeutics, Inc. Stock Price: Bottom Line

As of June 11, 2025, Monte Rosa Therapeutics, Inc.’s stock price is $5.180, which is up 1.97% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Monte Rosa Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.